vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Nextpower Inc. (NXT). Click either name above to swap in a different company.
Nextpower Inc. is the larger business by last-quarter revenue ($909.4M vs $598.7M, roughly 1.5× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 14.4%, a 26.4% gap on every dollar of revenue. On growth, Nextpower Inc. posted the faster year-over-year revenue change (33.9% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $118.5M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 11.1%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Nextpower Inc. (NXT) is a global energy technology provider based in Fremont, California.
EXEL vs NXT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $909.4M |
| Net Profit | $244.5M | $131.2M |
| Gross Margin | 95.6% | 31.7% |
| Operating Margin | 39.3% | 19.4% |
| Net Margin | 40.8% | 14.4% |
| Revenue YoY | 5.6% | 33.9% |
| Net Profit YoY | 74.8% | 13.8% |
| EPS (diluted) | $0.89 | $0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $909.4M | ||
| Q3 25 | $568.3M | $905.3M | ||
| Q2 25 | $555.4M | $864.3M | ||
| Q1 25 | $566.8M | $924.3M | ||
| Q4 24 | — | $679.4M | ||
| Q3 24 | $539.5M | $635.6M | ||
| Q2 24 | $637.2M | $719.9M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $131.2M | ||
| Q3 25 | $184.8M | $146.9M | ||
| Q2 25 | $159.6M | $157.2M | ||
| Q1 25 | $139.9M | $156.8M | ||
| Q4 24 | — | $115.3M | ||
| Q3 24 | $118.0M | $115.4M | ||
| Q2 24 | $226.1M | $121.7M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 31.7% | ||
| Q3 25 | 96.6% | 32.4% | ||
| Q2 25 | 96.5% | 32.6% | ||
| Q1 25 | 96.5% | 33.1% | ||
| Q4 24 | — | 35.5% | ||
| Q3 24 | 96.8% | 35.4% | ||
| Q2 24 | 97.2% | 33.0% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 19.4% | ||
| Q3 25 | 37.6% | 20.0% | ||
| Q2 25 | 33.6% | 21.5% | ||
| Q1 25 | 28.8% | 21.1% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | 25.2% | 21.0% | ||
| Q2 24 | 43.3% | 22.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 14.4% | ||
| Q3 25 | 32.5% | 16.2% | ||
| Q2 25 | 28.7% | 18.2% | ||
| Q1 25 | 24.7% | 17.0% | ||
| Q4 24 | — | 17.0% | ||
| Q3 24 | 21.9% | 18.2% | ||
| Q2 24 | 35.5% | 16.9% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.85 | ||
| Q3 25 | $0.65 | $0.97 | ||
| Q2 25 | $0.55 | $1.04 | ||
| Q1 25 | $0.47 | $1.05 | ||
| Q4 24 | — | $0.79 | ||
| Q3 24 | $0.40 | $0.79 | ||
| Q2 24 | $0.77 | $0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $952.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $2.2B |
| Total Assets | $2.8B | $3.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $952.6M | ||
| Q3 25 | $791.1M | $845.3M | ||
| Q2 25 | $1.0B | $743.4M | ||
| Q1 25 | $1.1B | $766.1M | ||
| Q4 24 | — | $693.5M | ||
| Q3 24 | $1.2B | $561.9M | ||
| Q2 24 | $1.0B | $471.9M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.2B | ||
| Q3 25 | $2.0B | $2.0B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.2B | $1.6B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $2.3B | $1.3B | ||
| Q2 24 | $2.1B | $1.1B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $3.8B | ||
| Q3 25 | $2.7B | $3.7B | ||
| Q2 25 | $2.8B | $3.4B | ||
| Q1 25 | $2.9B | $3.2B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | $3.0B | $2.8B | ||
| Q2 24 | $2.8B | $2.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $123.3M |
| Free Cash FlowOCF − Capex | $332.4M | $118.5M |
| FCF MarginFCF / Revenue | 55.5% | 13.0% |
| Capex IntensityCapex / Revenue | 0.2% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.36× | 0.94× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $587.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $123.3M | ||
| Q3 25 | $49.0M | $186.9M | ||
| Q2 25 | $211.4M | $81.3M | ||
| Q1 25 | $240.3M | $237.3M | ||
| Q4 24 | — | $143.8M | ||
| Q3 24 | $271.3M | $153.8M | ||
| Q2 24 | $119.5M | $120.8M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $118.5M | ||
| Q3 25 | $46.2M | $171.4M | ||
| Q2 25 | $208.5M | $70.1M | ||
| Q1 25 | $236.3M | $227.2M | ||
| Q4 24 | — | $134.9M | ||
| Q3 24 | $263.1M | $141.8M | ||
| Q2 24 | $113.0M | $118.0M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 13.0% | ||
| Q3 25 | 8.1% | 18.9% | ||
| Q2 25 | 37.5% | 8.1% | ||
| Q1 25 | 41.7% | 24.6% | ||
| Q4 24 | — | 19.9% | ||
| Q3 24 | 48.8% | 22.3% | ||
| Q2 24 | 17.7% | 16.4% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.5% | 1.3% | ||
| Q1 25 | 0.7% | 1.1% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | 1.5% | 1.9% | ||
| Q2 24 | 1.0% | 0.4% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 0.94× | ||
| Q3 25 | 0.27× | 1.27× | ||
| Q2 25 | 1.32× | 0.52× | ||
| Q1 25 | 1.72× | 1.51× | ||
| Q4 24 | — | 1.25× | ||
| Q3 24 | 2.30× | 1.33× | ||
| Q2 24 | 0.53× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
NXT
| Transferred Over Time | $763.9M | 84% |
| Transferred At Point In Time | $145.4M | 16% |
